Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Evolus Inc

EOLS ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$7.93

▲ +1.15%

Market Cap $523.78M · Vol 202.08K

Key Metrics

P/E Ratio

N/A

FWD: 54.59

Market Cap

$523.78M

Small Cap

Div Yield

N/A

EPS Growth

+89.77%

YoY

RSI (14)

33.27

Momentum

Beta

1.34

vs Market

52W High

$9.31

14.82% below

52W Low

$3.86

105.44% above

Volume

202.08K

Avg 343.19K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

77.81%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Evolus Inc (EOLS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EOLS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-14.73%

-2.76%

+17.83%

+58.28%

YTD

+19.25%

+10.29%

-16.00%

+0.25%

Financials & Valuation

TTM · Annual

Total Revenue	$297.18M
Net Income	$-51,641,000.00
Revenue Growth (YoY)	+21.18%
Gross Margin	64.22%
Operating Margin	-12.65%
Net Profit Margin	-17.38%
ROE	N/A
ROA · ROIC	-22.23% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	54.59
PEG Ratio	N/A
P/S	1.44
P/B	N/A
P/FCF	N/A
EPS Growth	+89.77%
Outstanding Shares	66.05M

Technical Indicators

50-Day SMA	$7.39
200-Day SMA	$6.09
RSI (14)	33.27
Beta	1.34
52-Week High	$9.31
52-Week Low	$3.86

Volume Today	202.08K
Avg Daily Volume (30D)	343.19K
Relative Volume	0.59x
Volatility (10D)	50.11
Volatility (30D)	73.76
Free Float	77.81%

Analyst Consensus

BUY

Current Price $7.93

Mean Target $15.00

52W Low$3.86 52W High$9.31

Current

Target

$3.86 $9.31

Current Analyst target

+89.16% upside potential · 7 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG005CX4HL7

ISINUS30052C1071

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +2.02% JNJ Johnson & Johnson +0.28% ABBV AbbVie Inc. +1.81% NVS Novartis AG +1.33% NOVN.S Novartis AG +1.68%

Company Profile

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.